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Abstract
Background: Depression is viewed as a major and increasing public health issue, as it causes high distress in the
people experiencing it and considerable financial costs to society. Efforts are being made to reduce this burden
by preventing depression. A critical component of this strategy is the ability to assess the individual level and
profile of risk for the development of major depression. This paper presents the cost-effectiveness of a personalized
intervention based on the risk of developing depression carried out in primary care, compared with usual care.
Methods: Cost-effectiveness analyses are nested within a multicentre, clustered, randomized controlled trial of a
personalized intervention to prevent depression. The study was carried out in 70 primary care centres from seven
cities in Spain. Two general practitioners (GPs) were randomly sampled from those prepared to participate in each
centre (i.e. 140 GPs), and 3326 participants consented and were eligible to participate. The intervention included
the GP communicating to the patient his/her individual risk for depression and personal risk factors and the
construction by both GPs and patients of a psychosocial programme tailored to prevent depression. In addition,
GPs carried out measures to activate and empower the patients, who also received a leaflet about preventing
depression. GPs were trained in a 10- to 15-h workshop. Costs were measured from a societal and National Health
care perspective. Qualityadjustedlife years were assessed using the EuroQOL five dimensions questionnaire.
The time horizon was 18 months.
(Continued on next page)
* Correspondence: anafezsez@gmail.com
1ParcSanitariSant Joan de Déu, FundacióSant Joan de Déu, C/Dr.
AntoniPujadas, 42, 08830 SantBoi de Llobregat, Barcelona, Spain
2Mental Health Policy Unit, Brain and Mind Centre, Faculty of Health
Sciences, University of Sydney, Sydney, Australia
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fernández et al. BMC Medicine  (2018) 16:28 
DOI 10.1186/s12916-018-1005-y
(Continued from previous page)
Results: With a willingness-to-pay threshold of €10,000 (£8568) the probability of cost-effectiveness oscillated from
83% (societal perspective) to 89% (health perspective). If the threshold was increased to €30,000 (£25,704), the
probability of being considered cost-effective was 94% (societal perspective) and 96%, respectively (health perspective).
The sensitivity analysis confirmed these results.
Conclusions: Compared with usual care, an intervention based on personal predictors of risk of depression
implemented by GPs is a cost-effective strategy to prevent depression. This type of personalized intervention in
primary care should be further developed and evaluated.
Trial registration: ClinicalTrials.gov, NCT01151982. Registered on June 29, 2010
Keywords: Depression, Risk assessment, Cost-effectiveness
Background
In Western societies depression is viewed as a major and
increasing public health issue, as it causes high levels of
distress for those who experience it and their relatives,
as well as considerable financial costs to society. Indeed,
in 2013 major depression ranked fourth in the top ten
causes of years lived with disability in Europe [1], with
an estimated economic burden of €113.4 billion, ex-
plained by the use of services, losses in productivity and
premature death due to suicide [2].
In an effort to reduce this burden, governments have
supported increases in clinical services for mental
disorders. However, despite this investment, the preva-
lence of depression has not changed. In community-
representative studies major depression reached an inci-
dence rate that is high (3.0%) relative to the number of
prevalent cases (4.7%) [3]; therefore, it will be very diffi-
cult to reduce the prevalence unless the incidence is also
reduced, and this is only possible by primary prevention.
In addition, evidence suggests that although effective
treatments for depression are available, they can reduce
the burden by only 20% [4] because not all cases are rec-
ognized and not all people with recognized depression
are treated and adhere to treatment.
Different studies have shown that depression is prevent-
able [5–7]. In addition, prevention of depression is rela-
tively good value for money [8]. However, the effect sizes
of prevention are small, and most of the interventions are
implemented by mental health specialists [5–7]. This jeop-
ardizes its translation to primary health care centres,
which may be a good setting for implementing preventive
interventions [9]. Primary prevention aims to avoid the
occurrence of disease by either eliminating the risk factors
or increasing resistance to disease, so its application re-
quires that its target population does not have the disease
(depression in our case). Classically, primary prevention of
depression is classified as ‘universal’ when it is applied to
the general population, ‘selective’ to participants with some
risk factor(s) for depression and ‘indicated’ to patients
with subthreshold depression (they have some symptoms
of depression but do not meet the criteria for diagno-
sis).The best primary prevention programme is likely to
be one which targets modifiable risk factors, empowers
individuals to address their risks and is inexpensive and
capable of large-scale dissemination [10]. The Predict-
Dalgorithm [11, 12] provides a quantification of major
depression risk as well as information on risk factors
for each individual that could guide prevention. We
have recently evaluated the effectiveness of this strat-
egy: compared with usual care, this new preventive
intervention reduced the incidence of depression by
more than 20% at 18 months [13]. This has been the
first trial evaluating the effectiveness of a preventive
intervention for depression based on the level and
profile of risk and conducted by general practitioners
(GPs). In this paper we present the results of the cost-
effectiveness analysis of this intervention.
Methods
The PredictD trial
Full details of the PredictD protocol and effectiveness
analysis are available elsewhere [13, 14]. Briefly, the
PredictD-Cluster, Controlled, Randomized Trial (CCRT)
was a national, multicentre, randomized controlled trial
with two parallel arms, cluster assignment by primary
care centre and 18 months of follow-up (from October
2010 to July 2012).
A total of 220 primary care centres from seven Spanish
cities (Barcelona, Bilbao, Granada, Jaen, Málaga, Valladolid
and Zaragoza) were approached. We conducted meetings
in each centre to explain the project and invite physicians
to participate; 118 (53.64%) out of the 220 centres were in-
terested in participating. Seventy centres (10 per city) out
of the 118 were randomly selected. A total of 193 physi-
cians from the 70 centres consented to participate. Of
those who accepted, we randomly selected two physicians
per centre (i.e. 140 physicians). Random selection was
conducted using sealed opaque envelopes by an independ-
ent researcher who was not part of the research team.
Randomization to intervention or control group was
Fernández et al. BMC Medicine  (2018) 16:28 Page 2 of 12
conducted at the centre level. In each city five centres
were assigned to the control group and five centres to the
intervention group.
Research assistants randomly selected four to six pa-
tients per day from the patients with an appointment
with the GP, using random starting points for each day,
generated using a random number generator. GPs
reviewed the list each day, excluding those patients
who were not eligible for the trial. A total of 8292 par-
ticipants were selected. Of these, 3056 were excluded in
this first stage for the following reasons: 1479 were < 18
or > 75 years old; 1039 attended the surgery on behalf
of the person who had the appointment; 153 would be
away (> 4 months) during the follow-up; 122 had a doc-
umented severe mental disorder; 121 did not speak or
understand Spanish; 88 had cognitive impairment; 54
had terminal illnesses. The process ended when there
were 26–27 eligible patients for each GP.
A total of 5236 persons were invited to participate in
the study by the research assistants. Of these, 1453 pa-
tients (27.28%) declined to participate. When compared
with participants, these non-participants were slightly
more likely to be male (38.4% versus 36.5%) but were of
similar age (50.5 versus 50.7 years).
The 3783 patients who agreed to participate were then
interviewed to detect major depression using the
Composite International Diagnostic Interview (CIDI). Of
the 3783 patients,457 (12.08%) met criteria for major
depression in the last 6 months and were consequently
excluded.
A total of 3326 patients (1663 in each arm), nested in
140 GPs from 70 primary care centres, composed the
sample of the trial. The total number of patients with
missing data in any of the outcome variables at any
point was 577 (17.35%).
Although patients did not consent to randomization,
patients at the intervention centre consented to receive
the intervention, and all patients agreed to data collec-
tion. Neither the patients nor the GPs were blind to the
intervention, which is common for trials that evaluate
psychosocial interventions [15].The interviewers who
assessed outcomes, however, were masked regarding
allocation to study group. Local Ethics and Human
Research Committees at each city approved the protocol.
The Spanish primary care context
The National Health System of Spain provides universal
coverage for citizens and foreign nationals (including
undocumented immigrants). It is funded through taxes
and free at the point of contact. Health care services are
distributed into Health Areas and Basic Health Zones
according to geographical, epidemiological and socio-
economic criteria. Each Health Area covers a population
of 200,000–400,000 inhabitants and is composed of
several Basic Health Zones, which are the minimum units
of health care organization. Basic Health Zones are orga-
nized around a primary care centre covering 5000–35,000
inhabitants. The primary care teams are composed of
GPs, paediatricians, nurses and, in some cases, social
workers. They provide a broad range of services, including
the treatment of common mental disorders (shared with
mental health specialists in severe cases) such as anxiety
or depression [16], health promotion and preventive ser-
vices. All the primary care centre staff members, including
the GPs, are salaried. GP salaries contain two elements: a
larger fixed payment and a smaller incentive, based on
elements such as numbers of patients assigned, fulfilment
of objectives, patterns of prescription and pay-for-
performanceincentives [17].
Interventions
Intervention group
The PredictD intervention has been described in detail
elsewhere [14]. Briefly, the intervention started with the
physician receiving the patient’s risk factors for depres-
sion and overall probability of developing depression in
the next 12 months, using the Spanish version of the
PredictD algorithm [11]. The PredictD algorithm is com-
posed of 12 risk factors: six are patient characteristics or
past events (sex, age, sex*age interaction, education,
childhood physical abuse, probable lifetime depression),
and six refer to current status (Short Form Health
Survey (SF-12) physical score, SF-12 mental score, dis-
satisfaction with unpaid work, number of serious prob-
lems in very close persons, dissatisfaction with living
together at home, taking medication for stress, anxiety
or depression). The PredictD algorithm provides, in
addition to the quantification of the overall risk of de-
pression, knowledge of those risk factors influencing a
given patient and that could guide a possible preventive
intervention. Once the risk was calculated, the GP com-
municated this risk to the patient, and they worked to-
gether on a plan to manage those individual risk factors.
This plan was tailored to the patients following a bio-
pyscho-family-social framework, emphasizing measures
to empower and activate the patients. In addition, all pa-
tients received a patient-oriented booklet on preventing
depression, based on basic recommendations for self-
care, including advice on exercise and sleep. All the GPs
in the intervention arm were trained in a 10- to 15-h
workshop on the prevention of depression using the
PredictD risk algorithm.
Control group
GPs in the control arm did not receive the training or
any information on their patients’ risk factors for depres-
sion or their probability of developing depression. They
were simply asked to treat their patients as usual.
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Economic analysis
The economic evaluation was conducted from two per-
spectives: (1) societal perspective, including the costs of
all types of health services (direct costs) and the costs
that stem from production losses (indirect costs), and
(2) a National Health System perspective (including only
direct costs from the Spanish public health services).
The time frame of this study was 18 months. Therefore,
we discounted both costs and effects at 3.5% following
National Institute for Health and Care Excellence
(NICE) recommendations [18]. All costs were expressed
in euros (€) for the reference year 2012.
Cost
We used a modified version of the Client Service Receipt
Inventory (CSRI) [19] to collect information about use
of health care resources, use of psychotropic drugs (anti-
depressants, anxiolytics and sedative-hypnotics) and lost
productivity.
Direct health costs were calculated by multiplying the
number of health service contacts/units (consultations,
hospital days, etc.) by their standard cost price. This unit
cost was retrieved from ‘Oblikue dataset (esalud)’
(http://www.oblikue.com/), which includes the official
health services tariffs of the different Spanish autono-
mous communities. Cost of medication was calculated
by multiplying cost price per daily dose, multiplied by
the number of prescription days recommended, as
recalled by the patient. Information about medication
costs was obtained from the Spanish Pharmaceutical
Vademecum (http://www.vademecum.es/). Indirect costs
consisted of the costs of being on sick leave from paid
work. Costs of work loss were calculated by multiplying
the days on sick leave by the minimum daily wage in
Spain according to the human capital approach. In
addition, self-reported presenteeism was assessed using
some questions from the World Health Organization
(WHO) Health and Work Performance Questionnaire
(HPQ) [20]. For this assessment, respondents first esti-
mated how many days during the past 4 weeks they had
been at work not being able to perform their job as
usual (A), and then, they rated their overall work per-
formance during these days using a 0–100 scale where 0
corresponds to doing no work at all (while at work) and
100 signifies top work performance (B). A score was cal-
culated as follows: ((100 – B)*A)*6. Here 6 is the period
of the follow-up (6 months).
Intervention costs included the cost of the booklet
(€0.16 per patient) and the cost associated with the
training of the physicians. Training was included in the
GPs’ general training programme during working time,
so no extra hours were worked or locums needed. No
charges were incurred for training venues, as the train-
ing was conducted in the health centres or other health
sector free venues. We included the cost of the trainer
(€100 per h), estimated at 10 h and 7 groups (€7000),
and the cost of the 70 dossiers delivered to the GPs with
the basic information (€700). The intervention was em-
bedded in the current practice. Participants in the inter-
vention group were required to meet at least three times
during the intervention (at baselineand at 6 and
12 months): in each of the three GP-patient interviews
the GP communicated to the patient specific and up-
dated information on his/her risk of depression, and
then the patient and GP worked on a personalized plan
for prevention of depression. These visits lasted approxi-
mately from 5 to 15 min, and this time generally was
proportional to the level of risk. If the GP considered that
the complexity of the case would require more visits, it
was proposed to the patient. The patient at his/her own
request could also propose new visits to the GP. All visits
that were made during the follow-up, both compulsory
and optional, were taken into account for costs.
The unit costs used are given in Table 1.
Health effects
Quality-adjusted life years (QALYs) were measured using
the EuroQol five dimensions questionnaire (EQ-5D). The
EQ-5D instrument has two parts. Part 1 is a self-reported
description of health problems according to a five-
dimensional classification (mobility, self-care, usual activ-
ities, pain/discomfort and anxiety/depression). Patients
mark one of three levels of severity (1 = no problems, 2 =
some/moderate problems and 3 = severe/extreme prob-
lems) in each dimension. Combinations of these categories
define a total of 243 different health states. For instance,
perfect health is coded as ’11111’. Each one of these health
states has a ’weight’ or ’utility’ based on community prefer-
ences (i.e. social tariffs), where 1 represents perfect health,
0 death and negative numbers symbolize health states that
are considered worse than death. Spanish social tariffs
were used to estimate the utility of health states described
by patients [21]. QALYs were calculated by multiplying
the utility by the amount of time a patient spent in a par-
ticular health state. Linear interpolation was used for tran-
sitions between health states at baseline and at 6, 12 and
18 months. Part 2 is avisual analogue scale (VAS), graded
from 0 (worst imaginable health status) to 100 (best im-
aginable health status), which is used by patients to esti-
mate the ’value’ of their health status. We transformed the
VAS to a scale from 0 to 1 and used it to have a ’proxy’ of
an ’individual tariff ’ and to calculate QALYs using it
(referred to in the results as QALYs-VAS) [22].
Statistical analysis
Analyses were performed based on the intention-to-treat
(ITT) principle, analysing all participants according to
their randomized treatment and using multiple
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imputations when outcomes were missing. Incremental
cost-effectiveness ratios (ICERs) were calculated as the
difference in the cost between the intervention and the
control group, divided by the difference in QALYs. The
incremental costs and incremental health effects were
modelled by generalized linear models (GLMs). We cal-
culated the intraclass correlation coefficients (ICCs) of
the health centre, GP and both, taking the costs and
QALYs as dependent variables. The ICCs for the health
centre were significant for the effect, while the ICC for
the GP was significant for the costs. Thus, we used
multilevel GLMs to account for such clustering effects.
GLMs were fitted using different distribution families
(Gaussian, inverse Gaussian, Poisson and gamma) and
link functions (identity and log). Mmodified Park tests
were used to select the appropriate family. To identify
the correct link function, we compared the model per-
formance of all permutations of candidate link and
Table 1 Unadjusted costs and effects, by group
Costs Unit cost (€2012) Mean costs,
control (95% CI)
Mean costs,
intervention (95% CI)
Unadjusted diff
(95%CI)a
P value
Costs associated to the intervention €0 €4.79 NA NA
Primary care physician €10.50 (centre visit),
€27.48 (home visit)
€96.61 (90.54 to 102.68) €91.46 (85.68 to 97.23) €–5.16 (–13.58 to 3.27) 0.230
Primary care nurse €10.03 (centre visit),
€25.37 (home visit)
€35.67 (28.74 to 42.59) €26.34 (21.23 to 31.45) €–9.32 * (–17.95 to –0.69) 0.032
Social worker €14.90 (centre visit),
€25.37 (home visit)
€0.63 (0.41 to 0.87) €0.46 (0.27 to 0.66) €–0.18 (–0.51 to 15) 0.293
Emergency visits to primary care €63.99 €33.07 (25.27 to 40.86) €29.05 (22.20 to 35.90) €–4.02 (–14.44 to 6.40) 0.451
Total primary care €162.75 (151.01 to 174.49) €146.17 (135.76 to 156.58) €–16.58 (–32.32 to –0.85) 0.039
Outpatient mental health (MH) visit €42.93 (psychiatrist),
€70.61 (psychologist),
€10.03 (MH nurse),
€19.22 (group therapy)
€16.16 (9.74 to 22.57) €16.31 (8.08 to 24.54) €0.15 (–10.31 to 10.62) 0.997
Antidepressant *Different values* €20.70 (0 to 72.8) €22.32 (0 to 76.77) €1.62 (–57.74 to 60.98) 0.658
Admission to psych.hospitalb €284.90 NA NA NA NA
Total mental health €45.19 (31.02 to 59.36) €34.40 (24.07 to 44.73) €–10.79 (–27.11 to 5.54) 0.184
Other outpatient specialists €51.08 €149.08 (122.96 to 175.19) €149.46 (122.53 to 176.40) €0.38 (–35.26 to 36.02) 0.973
Diagnostic tests *Different values* €212.86 (189.47 to 236.25) €198.24 (176.59 to 219.89) €–14.61 (–46.31 to 17.08) 0.368
Emergency visits to hospital €155.50 €96.18 (73.13 to 119.24) €92.82 (70.60 to 115.04) €–3.37 (–34.20 to 27.47) 0.831
Non-mental health-related
admissions
*Different values* €493 (134.79 to 852.27) €548.04 (0 to 1136.96) €54.51 (–141.48 to 250.50) 0.587
Total healthcare direct costs €1039.11 (819.24 to 1258.98) €1075.11 (849.70 to 1300.53) €36.01 (–132.02 to 204.04) 0.676
Sick leave €21.11/day €337.37 (122.08 to 552.68) €335.30 (96.60 to 574.03) €–2.08 (–126.1 to 121.94) 0.974
Total costs €1353.99 (1039.31 to 1668.66) €1394.83 (1020.07 to 1769.6) €40.85 (–178.21 to 259.91) 0.716
Units for sensitivity analysis
Extra intervention costsc 0 €31.72 NA NA
Private direct health costs *Different values* €174.13 (76.92 to 271.33) €126.00 (82.90 to 169.10) €–48.13 (–107.10 to 10.83) 0.099
Absenteeism €21.11/day €87.34 (57.27 to 117.42) €89.70 (63.38 to 116.01) €2.35 (–30.66 to 35.37) 0.888
Presenteeism €21.11/day €80.41 (36.78 to 124.04) €63.39 (34.42 to 92.34) €–17.02 (–52.93 to 18.81) 0.322
Effects Unit of the effect Effect gained control
(95% CI)
Effect gained intervention
(95%CI)
Unadjusted diff
(95%CI)a
P value
QALYs Mean 1.22 (1.20 to 1.24) 1.25 (1.23 to 1.26) 0.03 (–0.02 to 0.07) 0.240
QALYs-VAS Mean 1.05 (1.04 to 1.07) 1.08 (1.07 to 1.10) 0.03 (0.006 to 0.05)* 0.014
aThe means of the costs by group and the unadjusted difference have been calculated using univariatemaximum likelihood (ML)generalized linear model
(GLM) family gamma and link log (cost as dependent variable and group as the only independent variable) and the command margins in 20 imputed
databases. As it is not a linear model, the sum of the individual components of the costs may be slightly different to the total cost presented
bThere are only 8 participants who were admitted in an inpatient psychiatric unit, 7 in the control group and 1 in the intervention group. The length of
stay has a mean of 10 days
cExtra costs related to the intervention if hiring of the venue and additional hours of the physician were included
CI confidence interval,NA not applicable,QALY quality-adjusted life year, VAS visual analogue scale
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variance function using different diagnostic tests [23].
The best solution for costs was obtained using a gamma
family and a log link. For QALYs, the most adequate
family was Gaussian with an identity link.
All models were adjusted by their respective baseline
values (i.e. QALYs or cost), the individual risk of depres-
sion (i.e. risk score from the PredictD algorithm) and the
following variables,which were unbalanced at baseline
(and were not included in the PredictD algorithm): em-
ployment status, owner/occupier accommodation, per-
ception of safety inside/outside the home, anxiety
disorder, experiences of discrimination, city.
We accounted for missing outcomes by using multiple
imputations with chained equations under a missing at
random (MAR) framework. We generated 50 imputed
samples. Estimates for the descriptive analysis were com-
bined using Rubin’s rules [24].
The analytic focus on cost-effectiveness (or cost-utility ana-
lysis) emphasizes the estimation of the joint density of cost
and effects differences, the quantification of uncertainty sur-
rounding the ICER and the presentation cost-effectiveness
acceptability curves (CEACs). In that sense, in economic
evaluations it is considered inappropriate to carry out
separate and sequential hypothesis tests on differences in ef-
fects and costs to determine if incremental cost-effectiveness
should be estimated (i.e. hypothesis testing is not conducted,
so P values are not taken into consideration [25].
To deal with uncertainty, non-parametric bootstraps
were used to simulate 1000 ICERs per imputed database
(i.e. 50,000 ICERs in total), which were plotted on the
cost-effectiveness plane. CEACs were then constructed.
Each CEAC was derived from the net benefit approach:
Netmonetary benefit ¼ λ ΔEffectð Þ− ΔCostð Þ;
where λ represents the amount of money society is will-
ing to pay to gain one extra unit of effect. All boot-
strapped pairs of Δ Effect and Δ Cost (i.e. 50,000) were
used to calculate the CEACs. Willingness-to-pay values
ranged from €0 to 100,000 [26]. We have selected as op-
timal threshold of €30,000 per QALY ($32,058, £25,704),
following Spanish suggestions [27]. This threshold fits
into the cost-effectiveness threshold ranging between
£20,000 and 30,000 used by NICE [18]. However, it is
lower than the $50,000 suggested in the USA [28].
Sensitivity analyses
A number of sensitivity analyses were conducted in
order to assess the robustness of the results:
1. Modifying the perspective of analysis, i.e. including
only costs related to the outcome (primary health
services, mental health services and psychotropic)
and all the possible costs,i.e. private costs,
absenteeism and presenteeism, and potential
intervention-related costs including costs of hiring
the venue (€100 per day, per 2 days in 7 cities) plus
the costs associated with the time for which the
physician attended the course (€10.5 per visit per 60
visits in two days per 70 physicians)
2. Modifying the discount rate, both in costs and
effects, from 0 to 6%, following NICE
recommendations [18]
3. Modifying the unit costs by doubling and halving them
4. Modifying the statistical analyses— using seemingly
unrelated regressions (SURs), a method that consists
of a system of regression equations that recognize the
correlation between individual costs and outcomes
[29], a completers approach (applying inverse
probability weighting to address attrition bias) and
models adjusted only by cost or QALYs at baseline
Results
Participants
The participants in the two groups were similar with re-
gard to gender (63.6% female in the control group and
63.5% in the intervention group), age (51.5 and 50 years
in the control and intervention groups, respectively),
marital status (68.4% and 69.9% were married in the
control and intervention groups, respectively) and edu-
cational level (42.2% and 44.3% had primary level educa-
tion, respectively). However, they differed in key aspects
related to the trial. Participants in the intervention group
had a higher risk of depression,a slightly worse mental
health-related quality of life, more anxiety-related symp-
toms and a greater proportion of people who answered
affirmatively to the two questions we use as a lifetime
screen for depression [30]. In addition, there were differ-
ences in employment status, owner-occupier of an ac-
commodation, perception of safety inside-outside the
home and experiences of discrimination. Further details
of trial participants are given by Bellon et al. [13].
Table 1 presents the unadjusted mean costs and effects
for the intervention and control groups.
Cost-effectiveness analyses
Table 2 shows the adjusted means and the ICERs.
From a societal perspective the new intervention is
dominant, as the increment in cost is negative and the
effects are positive. However, although most (97.4%) of
the incremental effects were plotted in the Eastern quad-
rants (new intervention more effective), the level of un-
certainty related to the costs is quite high, with half of
them in the Northern quadrants (new intervention more
expensive) and the other half in the Southern quadrants
(new intervention less expensive). These results are
depicted in Fig. 1, left column.
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The acceptability curve is shown in Fig. 2. At the €30,000
per QALY ($32,058,£25,704) threshold the probability that
the PredictD intervention would be seen as cost-effective
was 94%. This probability increased to 98% when consider-
ing the effect in terms of the QALYs-VAS. However, these
values decreased to 83% and 89%, respectively, when a
threshold of €10,000 ($10,686, £8568) was used.
From a National Health System perspective, the incremen-
tal cost for QALYs gained was €1326. The cost for QALYs-
VAS was €1085.45. Similarly as shown for the societal per-
spective, although most of the incremental effects were also
plotted in the Eastern quadrants, the level of uncertainty re-
lated to the costs was quite high (Fig. 1, right column). Fig-
ure 3 depicts the acceptability curve from a National Health
System perspective. Similarly, at the €30,000 per QALY
threshold ($32,058,£25,704), the probability that the PredictD
intervention is cost-effective was 96%, increasing to almost
100% when the effect was measured using QALYs-VAS.
These values decreased to 89% and 96% when a threshold of
€10,000 ($10,686, £8568) was used.
Sensitivity analysis
Table 3 summarizes the sensitivity analysis. The scenario
that only considered the costs directly related to primary
and mental health care was the best. The worst scenario
was the one where the costs were doubled. However, the
values were quite similar.
Discussion
Summary
Over the 18-month evaluation period, the PredictD
intervention was found to be efficient. The cost-
effectiveness advantage arises from the finding that the
PredictD intervention increases quality of life while not
significantly increasing overall costs. The sensitivity ana-
lyses confirm the robustness of the results.
Strengths and limitations
This is the first economic evaluation nested in a ran-
domized trial to evaluate the effectiveness of universal
prevention of depression in adults implemented by GPs.
Major strengths include the large sample (more than
3000 primary care attendees) and a follow-up time of
18 months, which is longer than that for most depres-
sion prevention trials.
Nonetheless, the results of this study should be con-
sidered with the following limitations in mind. First, due
to the recruitment procedure, our study may have
under-represented patients who attend infrequently [31];
however, frequent attenders are more at risk of major
depression [32] and are most in need of prevention.
Second, intervention and control groups were unbal-
anced on some individual variables, so that participants
had a higher risk of depression in the intervention
group. This is not unusual in cluster randomized control
trials, where an imbalance in the characteristics of par-
ticipants can creep in because randomization occurs at
the level of centre [33]. To solve that, we have adjusted
the results for the unbalanced variables. Third, the pa-
tients were not blind to the intervention. They may have
modified their responses to satisfy the researchers/GPs.
Fourth, the information on use of services was collected
by means of self-report. Some bias in recall may be ex-
pected, although it is quite likely that this bias was
equally distributed between the intervention and control
groups. In addition, we have not taken into account in-
formal care-related costs and costs from general medica-
tion. As depression has an impact on physical health, it
is possible that this has been affected, making the costs
associated with depression possibly higher than we have
calculated in our study. On the other hand, the cost as-
sociated with the training of the GP was translated to
the patient level by dividing by the number of partici-
pants in the trial and not by the total number of pa-
tients, which would be more appropriate in real practice.
Consequently, the costs associated with the intervention
in real practice would be even lower. Fifth, in our study,
only 32.4% and 36.6% of patients, in the control and the
Table 2 Incremental cost-effectiveness ratio (ICER)-adjusted ana-
lysis: main scenarios
Effect Ajdusteda mean difference
(95% bootstrapped CI) and ICER
Main Outcome
Societal perspective
Incremental cost –16.38(–615 to 503)
Incremental QALY 0.02(–0.00 to 0.04)
ICER (cost per QALY gained) Dominant
National Health perspective
Incremental cost 23.88 (–149 to 215)
Incremental QALY 0.02 (–0.00 to 0.04)
ICER (cost per QALY gained) €1327/QALY
Secondary outcomes
Societal perspective
Incremental cost –16.38(–615 to 503)
Incremental QALY-VAS 0.02 (0.01 to 0.03)
ICER (cost per QALY-VAS gained) Dominant
National Health perspective
Incremental cost 23.88 (–149 to 215)
Incremental QALY-VAS 0.02(0.01 to 0.03)
ICER (cost per QALY-VAS gained) €1085/QALY
aAll the analyses have been adjusted by baseline variables: employment status,
owner/occupier of an accommodation, perception of safety inside/outside the
home, anxiety disorder, experiences of discrimination,city, in addition to the risk
of depression and the respective baseline value (i.e. costs or QALYs)
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Fig. 1 Cost-effectiveness planes
Fig. 2 Cost-effectiveness acceptability curves (CEACs): societal perspective
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intervention group, respectively, answered yes to the two
questions of lifetime screen for depression (except in the
6 months prior to the baseline interview, in which no
patient suffered major depression according to the CIDI)
[13]. The predictive positive value of responding yes to
these two questions is 18% [30],and in our study the
proportion of patients who truly suffered a first episode
of depression before recruitment was 5.8% and 6.6% in
the control and the intervention group, respectively.
Therefore, from this point of view, our study is largely
based (approximately 94% of participants) on primary
prevention of the onset of depression (first episode).
Lastly, the generalizability of our findings may be limited
because costs associated with primary care processes in
Spain are less costly than in other Western countries,
due to the fact that GPs are salaried [17]. However, in
these other countries, such as the USA, the cost-
effectiveness threshold is also higher.
Comparison with existing literature
To the best of our knowledge, there are only two eco-
nomic evaluations focused on the prevention of depres-
sion that can be compared with ours. Hunter et al. [34]
carried out an economic modelling study based on the
PredictD risk algorithm concluding that identifying non-
depressed general practice attendees at highrisk of de-
pression using the algorithm PredictD and providing
them with a psychosocial preventive programme was po-
tentially more cost-effective than the current practice.
At a threshold of £25,000 (€30,000,$31,200 ) per QALY
the probability of being cost-effective was around 70%.
Our analysis showed that the probability of being cost-
effective at this threshold is even higher.
Similarly, Van den Berg et al. [35] built up a model to
estimate the cost-effectiveness of preventing depression
in people with subthreshold symptoms of depression op-
portunistically approached in primary care practices.
The intervention consisted of a self-help manual with in-
structions on cognitivebehaviour self-help in mood man-
agement plus up to six short telephone calls to support
the participants while working through the manual.
Given a willingness to pay of €30,000 ($32,058,£25,704)
per disability-adjusted life year (DALY), the probability
that the intervention was cost-effective was around 80%.
Again, our intervention had a higher probability (96%)
of being cost-effective at the same threshold. It may be
hypothesized that participants in our trial benefited from
a tailored face-to-face intervention as well as from the
opportunistic reviews when they consulted their GPs
related to other issues.
However, in both economic studies [34, 35] strategies
for preventing depression in high-risk patients were
evaluated (selective or indicated prevention), whereas in
our study we followed a universal and personalized
prevention implemented by GPs.
Implications for practice
This intervention differs from other interventions to
prevent depression because it is tailored to each patient’s
individual level and profile risk. This approach parallels
primary prevention of cardiovascular diseases in primary
care, although the risk factors involved and their manage-
ment are different. Indeed, our intervention did not in-
crease costs because it was embedded into the day-to-day
practice. Our study showed that universal prevention of
depression in adults, using the PredictD intervention and
implemented by GPs, has a high probability of being cost-
effective compared to usual care. However, with our study
we cannot know if this type of universal prevention would
be more cost-effective than other types of primary preven-
tion (selective or indicated). Further trials comparing these
types of prevention and different frequencies of risk evalu-
ation are need. GPs generally perceive that they do not
have enough time to perform preventive activities, and
Fig. 3 Cost-effectiveness acceptability curves (CEACs): National Health System perspective
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Table 3 Sensitivity analysis
Sensitivity analysisa Adjusted mean difference
(95% CI ) and ICER
Incremental net benefit: probability intervention is seen as effective with
a threshold of:
€0 €10,000 €30,000 €50,000 €100,000
A. Perspective
Costs only related to primary cre and mental health
Incremental cost €–43.61 (–186 to 10)
Incremental QALY 0.02(–0.00 to 0.04)
ICER (cost per QALY gained) Dominant 0.9250 0.9852 0.9808 0.9784 0.9765
All the costs
Incremental cost €–10.32 (–253 to 281)
Incremental QALY 0.02(–0.00 to 0.04)
ICER (cost per QALY gained) Dominant 0.537 0.8989 0.9659 0.9724 0.9751
B. Discount rate (societal perspective)
Discount rate: 0%
Incremental cost €–16.19 (–612 to 500)
Incremental QALY 0.02 (0.00 to 0.04)
ICER (cost per QALY gained) Dominant 0.5309 0.8347 0.9413 0.9606 0.9710
Discount rate: 6%
Incremental cost €–16.51 (–618 to 505)
Incremental QALY 0.02(–0.00 to 0.04)
ICER (cost per QALY gained) Dominant 0.5316 0.8301 0.93855 0.9584 0.9694
C. Unit costs (societal perspective)
Cost doubled
Incremental cost €–32.76 (–1231 to 1006)
Incremental QALY (social tariffs) 0.02(–0.00 to 0.04)
ICER (cost per QALY gained) Dominant 0.5316 0.734 0.8874 0.9301 0.9594
Costs halved
Incremental cost €–8.19 (–308 to 252)
Incremental QALY (social tariffs) 0.02(–0.00 to 0.04)
ICER (cost per QALY gained) Dominant 0.5316 0.9140 0.9635 0.9699 0.9734
D. Analytical strategy
Seemingly unrelated equations (societal perspective)
Incremental cost €–38 (–251 to 174)
Incremental QALY (social tariffs) 0.02(–0.00 to 0.04)
ICER (cost per QALY gained) Dominant 0.6383 0 .9307 0.9711 0.9750 0.9767
Completers analysis (societal perspective)b
Incremental cost €–14.46 (–1217 to 1456)
Incremental QALY (social tariffs) 0.02 (0.01 to 0.04)
ICER (cost per QALY gained) Dominant 0.48 0.761 0.888 0.923 0.962
Models adjusted only by costs or QALYs at baseline (societal perspective)
Incremental cost €118.52 (–909€ to 1497)
Incremental QALY (social tariffs) 0.02 (0.01 to 0.04)
ICER (cost per QALY gained) €5644/QALY 0.3864 0.7165 0.8727 0.9218 0.9606
aAll the analyses have been adjusted by the following baseline variables: employment status, owner/occupier of an accommodation, perception of safety inside/
outside the home, anxiety disorder, experiences of discrimination,city (unless something elsewas stated), in addition to the risk of depression and the respective
baseline value (i.e. costs or QALYs)
bCompleters analyses were weighted using inverse probability weighting
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they may agree to do so only for high-risk patients.
Another possibility would be to provide universal preven-
tion to patients by mean of a scalable and cheap strategy
(e.g. through apps and smartphones), reserving the inter-
vention of GPs only in cases of high risk of depression.
Our research team is currently conducting a new trial with
the latter strategy (the e-PredictD study).
Conclusions
The PredictD intervention is likely to be perceived as
cost-effective, from both a societal and National Health
System perspective, compared to usual care.There is,
therefore, both a clinical and an economic case for sup-
porting the implementation of this intervention, which
is based on the level and profile of risk for depression, in
primary care practices. However, this intervention
should be further developed and evaluated in other
countries.
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